Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cannabinoid based therapeutics - CNBX Pharmaceuticals

Next Previous
Search
Drug Profile

Research programme: cannabinoid based therapeutics - CNBX Pharmaceuticals

Alternative Names: CBNA - CNBX Pharmaceuticals

Latest Information Update: 28 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cannabics Pharmaceuticals
  • Developer CNBX Pharmaceuticals; Technion - Israel Institute of Technology
  • Class Antineoplastics; Cannabinoids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in Israel
  • 18 Oct 2022 CNBX files for a PCT patent application for cannabinoids-based neoadjuvant cancer therapy in USA
  • 13 Oct 2022 CNBX Pharmaceuticals files for patent protection with US Patent and Trademark Office (USPTO) and with the Israel Patent Office for “Composition and method for treating cancer with cannabinoids” in US and Israel

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top